NADK2

Across TCGA pan-cancer cohorts, NADK2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated NADK2 data layer compared with 27 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher NADK2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated NADK2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and GBM show a favorable association.

CCRCC, HNSC, and PDAC are the cancer types where NADK2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	II,III,IV	0.272	0.822	.002	15	view →
HNSC	OS	Median	All	0.793	0.899	.022	13	view →
PDAC	OS	Median	II,III,IV	0.412	0.625	.004	11	view →
UCEC	DFS	Median	All	0.933	1.000	.015	8	view →
LSCC	DFS	Quartile	All	0.460	1.000	.013	5	view →
LUAD	DFS	Quartile	III,IV	1.000	0.498	.030	3	view →
GBM	DFS	Median	All	0.439	0.313	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

NADK2–CCRCC (DFS)

Open the CCRCC breakdown →